SEC Form 4 · accession 0001871714-26-000002
TENAX THERAPEUTICS, INC. · TENX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Thomas Giordano
Officer — CEO · Director
Period of report
Sep 11, 2026
Accepted (ET)
Sep 15, 2026 · 9:38 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000034956
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 11, 2026 | P | 6,000 | $1.875 | A | 17,324 | D | |
| Common StockF2 | Sep 15, 2026 | P | 4,850 | $1.8221 | A | 22,174 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $13.30 | holding | — | — | — | — | Jan 9, 2036 | Common Stock | 450,000 | 450,000 | D |
| Stock Option (right to buy)F4 | $5.89 | holding | — | — | — | — | May 16, 2035 | Common Stock | 1,400,000 | 1,400,000 | D |
| Stock Option (right to buy)F5 | $3.549 | holding | — | — | — | — | May 17, 2034 | Common Stock | 218 | 218 | D |
| Stock Option (right to buy) | $5.94 | holding | — | — | — | Dec 10, 2025 | Dec 10, 2034 | Common Stock | 1,241,500 | 1,241,500 | D |
| Stock Option (right to buy)F6 | $992.00 | holding | — | — | — | — | Jun 9, 2032 | Common Stock | 125 | 125 | D |
| Stock Option (right to buy)F7 | $3,152.00 | holding | — | — | — | — | Jul 6, 2031 | Common Stock | 157 | 157 | D |
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $1.87 to $1.88. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- F2This transaction was executed in multiple trades at prices ranging from $1.82 to $1.83. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- F3The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
- F4The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
- F5The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
- F6The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
- F7The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.